Published • loading... • Updated
Treatment Intensification Slows Metastatic Hormone-Sensitive Prostate Cancer
Summary by MedPage Today
5 Articles
5 Articles
Treatment Intensification Slows Metastatic Hormone-Sensitive Prostate Cancer
(MedPage Today) -- CHICAGO -- Men with metastatic castration-sensitive prostate cancer (mCSPC) and DNA repair alterations had significantly longer progression-free survival (PFS) with a targeted drug plus an androgen receptor pathway inhibitor...
·New York, United States
Read Full Article
informacion.es+2 Reposted by 2 other sources
A new combination of drugs, the enzalutamide androgen inhibitor and the talazoparib PARP inhibitor, has shown a 52% reduction in the risk of progression or death in patients with metastatic prostate cancer with altered DNA repair genes. Thus, it follows from the results of the phase 3 trial named TALAPRO-3, in which Vall d'Hebron has participated the Institute of Oncology (VHIO) and which has been presented at the Congress of the American Societ…
Coverage Details
Total News Sources5
Leaning Left0Leaning Right0Center1Last UpdatedBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium
